Viatris Fails Phase 3 Study of MR-139 for Blepharitis

Viatris announced that its phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.

The MR-139 3001 phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks. 

"Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the phase 3 program, which may include revising the planned additional phase 3 study. Thank you to the patients and investigators who contributed to the trial," Viatris Chief R&D Officer Philippe Martin said in a company news release. 

In June 2025, Viatris announced positive top-line results from its phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. The company also announced positive topline results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia.